UPB

1.59020.50%
MK

Marcella Kuhlman Ruddy

Chief Medical Officer

Dr. Marcella Kuhlman Ruddy, also known as Marcie, M.D., M.S., serves as an Independent Director at Upstream Bio, Inc. since February 2023. She served as Non-Executive Director at Polarean Imaging plc since August 25, 2022 until 2024. She serves as Chief Medical Officer of Tectonic Therapeutic, Inc. since July 2021. She joined the Tectonic Therapeutic, Inc. in July 2021. Prior to joining Tectonic, she oversaw the development pipeline in immunology and inflammation as Vice President, Global Program Direction for Immunology/Inflammation at Regeneron and was the program leader for Dupixent through numerous approvals and initiations of many phases 3 programs in the US and worldwide. Before Regeneron, she held clinical leadership positions at Alnylam, EMD Serono and Merck Research labs where she oversaw the early clinical development of programs across multiple therapeutic areas including inflammation, respiratory, muscle, metabolic and rare diseases. She is a board-certified pulmonologist who previously held a staff position in the Pulmonary Division at Massachusetts General Hospital, Boston where she was the Director of the Adult Cystic Fibrosis Center as well as a Member of the Partner’s Asthma Center. She has held multiple senior management positions over her career to date, including Merck & Co. Inc., Alnylam Pharmaceuticals, Inc, Regeneron Pharmaceuticals Inc. and at Tectonic Therapeutic where she has been employed as Chief Medical Officer since July 2021. She earned her undergraduate degree AB (Bachelor of Arts) in History from Princeton University, her MD/M.S from Washington University in St. Louis and completed her pulmonary critical care fellowship at Harvard Medical School/Brigham and Women’s Hospital in Boston. He is an Independent Director of Sionna Therapeutics, Inc. from January 06, 2025.

Positions